Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS: A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [488]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities, and study methodologies33.”
From Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients diagnosed with kidney disease, hypertension, and covered under Medicaid insurance are at higher risk for poor visual outcomes13–24.”
From Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults and early detection is critical for timely management to prevent vision loss1,2.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Artificial intelligence (AI) is an accurate screening tool for diabetic retinopathy (DR), the leading cause of blindness among working-aged adults.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“Statins, however, did not affect DR severity in the few studies in which this was evaluated, although not as a primary outcome (35,36).”
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477 · cited 1×
“If data on age at diagnosis of diabetes were available in these studies, participants were classified as type 1 if they were diagnosed before age 30 years and as type 2 if they were diagnosed with diabetes after age 30 years, as previously used in one study (7).”
Self-citationKlein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Self-citation
Cited by
Items 301–400 of 1,029
Enhanced Expression of NLRP3 Inflammasome-Related Inflammation in Diabetic Retinopathy
Chen, H., Zhang, X., Liao, N., Mi, L., Peng, Y., Liu, B., Zhang, S., & Wen, F. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22816 · Cited by 110
“Diabetic retinopathy (DR), a frequent microvascular problem associated with diabetes mellitus, is the main cause of blindness worldwide.(1,2) Timely interference for those at high risk of sight-threatening problems linked to DR, including diabetic macular edema and proliferative DR (PDR), is critical to preventing vis…”
BackgroundSelf-citationDavey, G. C., Patil, S. B., Oâ€TMLoughlin, A., & Oâ€TMBrien, T. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00086 · Cited by 113
“Hyperglycemia (20), hypertension (21), and dyslipidemia are considered as the major risk factors for DR (22).”
BackgroundLncRNAs: key players and novel insights into diabetes mellitus
He, X., Ou, C., Xiao, Y., Han, Q., Li, H., & Zhou, S. (2017) · Oncotarget · doi:10.18632/oncotarget.19921 · Cited by 108
“Diabetic retinopathy (DR) is one of the most common complications of DM and a leading cause of catastrophic vision loss in developed nations [116].”
BackgroundLi, W., Jin, L., Cui, Y., Nie, A., Xie, N., & Liang, G. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01405-3 · Cited by 108
Xie, H., Zhang, C., Liu, D., Yang, Q., Tang, L., Wang, T., Tian, H., Lü, L., Xu, J., Gao, F., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05299-x · Cited by 107
Self-citationMetabolic Dysregulation and Neurovascular Dysfunction in Diabetic Retinopathy
Yumnamcha, T., Guerra, M. H., Singh, L. P., & Ibrahim, A. S. (2020) · Antioxidants · doi:10.3390/antiox9121244 · Cited by 112
“As the number of cases of diabetes is expected to increase from 366 million in 2011 to 552 million in 2030 [5], DR will become an even larger problem in the near future [6].”
BackgroundNovel therapeutic targets in diabetic macular edema: Beyond VEGF
Urias, E. A., Urias, G. A., Monickaraj, F., McGuire, P. G., & Das, A. (2017) · Vision Research · doi:10.1016/j.visres.2017.06.015 · Cited by 104
Vitamin D and diabetes mellitus: Causal or casual association?
Grammatiki, M., Rapti, E., Karras, S. Ν., Ajjan, R., & Kotsa, K. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9403-y · Cited by 117
Sergeys, J., Etienne, I., Hove, I. V., Lefevere, E., Stalmans, I., Feyen, J. H. M., Moons, L., & Bergen, T. V. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-25372 · Cited by 106
Roy, B. (2025) · Medical Sciences · doi:10.3390/medsci13030087 · Cited by 131
Management Paradigms for Diabetic Macular Edema
Mitchell, P., & Wong, T. Y. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.11.012 · Cited by 115
Self-citationChatziralli, I., Sergentanis, T. Ν., & Sivaprasad, S. (2016) · Retina · doi:10.1097/iae.0000000000001070 · Cited by 102
(2019) · International Journal of Ophthalmology · doi:10.18240/ijo.2019.02.19 · Cited by 96
Self-citationExpression of Human ACE2 in Lactobacillus and Beneficial Effects in Diabetic Retinopathy in Mice
Verma, A., Xu, K., Du, T., Zhu, P., Liang, Z., Liao, S., Zhang, J., Raizada, M. K., Grant, M. B., & Li, Q. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.007 · Cited by 99
Gu, C., Zhang, H., & Gao, Y. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30213 · Cited by 102
“The major risk factors contributing to DR include hyperglycemia, hypertension, and dyslipidemia (Yau et al., 2012).”
BackgroundAdvanced Glycation End-Products and Diabetic Neuropathy of the Retina
Oshitari, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032927 · Cited by 113
“This includes clinically significant diabetic macular edema and proliferative diabetic retinopathy [5].”
BackgroundGuo, H., Wu, H., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086978 · Cited by 122
Vision Loss Expert Group of the Global Burden of Disease Study, Curran, K., Pető, T., Jonas, J. B., Friedman, D. S., Kim, J. E., Leasher, J. L., Tapply, I. H., Fernandes, A. G., Cicinelli, M. V., et al. (2024) · Eye · doi:10.1038/s41433-024-03101-5 · Cited by 134
“…as one of the most common causes of blindness and vision impairment among the working-age population; however, this is not true for some countries, such as the United Kingdom, due to the implementation of national DR strategies aimed at identifying and treating patients with this condition [2–9].”
Self-citationCichosz, S. L., Johansen, M. D., & Hejlesen, O. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815611680 · Cited by 101
DRNet: Segmentation and localization of optic disc and Fovea from diabetic retinopathy image
Hasan, M. K., Alam, M. A., Elahi, M. T. E., Roy, S., & Martí, R. (2020) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2020.102001 · Cited by 105
Yu, Z., Zhang, T., Gong, C., Sheng, Y., Lü, B., Zhou, L., Ji, L., & Wang, Z. (2016) · Scientific Reports · doi:10.1038/srep34306 · Cited by 111
Vessel extraction from non-fluorescein fundus images using orientation-aware detector
Yin, B., Li, H., Sheng, B., Hou, X., Chen, Y., Wu, W., Li, P., Shen, R., Bao, Y., & Jia, W. (2015) · Medical Image Analysis · doi:10.1016/j.media.2015.09.002 · Cited by 100
Deep learning based early stage diabetic retinopathy detection using optical coherence tomography
Li, X., Shen, L., Shen, M., Tan, F., & Qiu, C. S. (2019) · Neurocomputing · doi:10.1016/j.neucom.2019.08.079 · Cited by 107
Hwang, H. S., Chae, J. B., Kim, J. Y., & Kim, D. Y. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22725 · Cited by 99
“Diabetic retinopathy (DR) is the most common retinal vascular disease and the most common cause of moderate and severe vision loss in individuals of working ages.(1) Retinal vein occlusion (RVO) is the second-most common type of retinal vascular disease.”
BackgroundLu, J., Zhang, Z., Ma, X., Fang, S., & Qin, X. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107886 · Cited by 99
Cohort Profile: The Singapore Epidemiology of Eye Diseases study (SEED)
Majithia, S., Tham, Y.-C., Chee, M.-L., Nusinovici, S., Teo, C. L., Chee, M.-L., Thakur, S., Soh, Z. D., Kumari, N., Lamoureux, E., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyaa238 · Cited by 97
Self-citationThe Effect of Diet and Lifestyle on the Course of Diabetic Retinopathy—A Review of the Literature
Bryl, A., Mrugacz, M., Falkowski, M., & Zorena, K. (2022) · Nutrients · doi:10.3390/nu14061252 · Cited by 112
“Thus, a substantial number of DM patients had various grades of DR [11].”
BackgroundSahajpal, N., Goel, R. K., Chaubey, A., Aurora, R., & Jain, S. K. (2018) · Current Protein and Peptide Science · doi:10.2174/1389203719666180928123449 · Cited by 108
Alzheimer’s disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics links
Rojas, M., Chávez-Castillo, M., Bautista, J., Ortega, Á., Nava, M., Salazar, J., Díaz-Camargo, E., Medina, O., Rojas-Quintero, J., & Bermúdez, V. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i6.745 · Cited by 94
Nanomedicine and drug delivery to the retina: current status and implications for gene therapy
Tawfik, M., Chen, F., Goldberg, J. L., & Sabel, B. A. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02287-3 · Cited by 101
Optical coherence tomography angiography of the retina and choroid in systemic diseases
Chua, J., Tan, B., Wong, D. W. K., Garhöfer, G., Liew, X. W., Popa‐Cherecheanu, A., Chin, C. W. L., Miléa, D., Chen, C., & Schmetterer, L. F. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101292 · Cited by 105
Diabetic Complications in Obese Type 2 Diabetic Rat Models
Katsuda, Y., Ohta, T., Miyajima, K., Kemmochi, Y., Sasase, T., Tong, B., Shinohara, M., & Yamada, T. (2014) · Experimental Animals · doi:10.1538/expanim.63.121 · Cited by 95
Eye Care Utilization Among Insured People With Diabetes in the U.S., 2010–2014
Benoit, S. R., Swenor, B., Geiss, L. S., Gregg, E. W., & Saaddine, J. B. (2019) · Diabetes Care · doi:10.2337/dc18-0828 · Cited by 97
The retinal renin–angiotensin system: Roles of angiotensin II and aldosterone
Wilkinson‐Berka, J. L., Agrotis, A., & Deliyanti, D. (2012) · Peptides · doi:10.1016/j.peptides.2012.04.008 · Cited by 106
Lim, G., Bellemo, V., Xie, Y., Lee, X. Q., Yip, M. Y. T., & Ting, D. S. W. (2020) · Eye and Vision · doi:10.1186/s40662-020-00182-7 · Cited by 96
“Since one-third of diabetic patients have underlying DR, this would translate to approximately 250 million people suffering from DR by the year 2035 [2 – 4].”
BackgroundGaborit, B., Julla, J.-B., Besbes, S., Proust, M., Vincentelli, C., Alos, B., Ancel, P., Alzaid, F., Garcia, R., Mailly, P., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz069 · Cited by 95
Song, J. H., Chen, S., Liu, X., Duan, H., Kong, J., & Li, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144406 · Cited by 95
Self-citationCavan, D. A., Makaroff, L., Fernandes, J. D. R., Sylvanowicz, M., Ackland, P., Conlon, J., Chaney, D., Malhi, A., & Barratt, J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.023 · Cited by 95
Risk Factors of Thyroid Dysfunction in Patients With Type 2 Diabetes Mellitus
Ogbonna, S. U., & Ezeani, I. U. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00440 · Cited by 108
Yokomizo, H., Maeda, Y., Park, K., Clermont, A. C., Hernandez, S. L., Fickweiler, W., Li, Q., Wang, C., Paniagua, S. M., Simão, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6627 · Cited by 104
A Systematic Investigation on Complement Pathway Activation in Diabetic Retinopathy
Hameed, S. S., Vishwakarma, S., Chhablani, J. K., Tyagi, M., Pappuru, R. R., Jakati, S., Chakrabarti, S., & Kaur, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00154 · Cited by 103
Zaiou, M. (2020) · Cells · doi:10.3390/cells9030659 · Cited by 96
“This disease affects approximately one-third of diabetic patients [60] and up to 80% of all patients who have had diabetes for 20 years or more [61].”
BackgroundFan, W., Wang, K., Falavarjani, K. G., Sagong, M., Uji, A., Ip, M. S., Wykoff, C. C., Brown, D. M., Hemert, J. I. V., & Sadda, S. R. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.05.024 · Cited by 94
Evolution of Diabetes Technology
Dovč, K., & Battelino, T. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.009 · Cited by 132
Ghazal, M. A., Ali, S., Mahmoud, A. H., Shalaby, A. M., & El-Baz, A. S. (2020) · IEEE Access · doi:10.1109/access.2020.2974158 · Cited by 94
Burden of Diabetes and Prediabetes in Nepal: A Systematic Review and Meta-Analysis
Shrestha, N., Mishra, S. R., Ghimire, S., Gyawali, B., & Mehata, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00884-0 · Cited by 105
Interventions to increase attendance for diabetic retinopathy screening
Lawrenson, J. G., Graham-Rowe, E., Lorencatto, F., Burr, J., Bunce, C., Francis, J. J., Aluko, P., Rice, S., Vale, L., Peto, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012054.pub2 · Cited by 92
Pan, J., Chen, D., Yang, X., Zou, R., Zhao, K., Cheng, D., Huang, S., Zhou, T., Yang, Y., & Chen, F. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.05.018 · Cited by 97
Retinal Neurodegeneration in Diabetic Patients Without Diabetic Retinopathy
Ferreira, J., Alves, M., Dias‐Santos, A., Costa, L. B. D., Santos, B. O., Cunha, J. P., Papoila, A. L., & Pinto, L. A. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20215 · Cited by 93
“More than 93 million people currently suffer some sort of eye damage from diabetes.(3) In Portugal, the PREVADIAB study found a diabetes prevalence of 11.”
Backgroundfor the Medisoft Audit Group, Bailey, C., Chakravarthy, U., Lotery, A. J., Menon, G., & Talks, J. S. (2017) · Eye · doi:10.1038/eye.2017.125 · Cited by 93
Self-citationFan, X., Xu, M., Ren, Q., Fan, Y., Liu, B., Chen, J., Wang, Z., & Sun, X. (2022) · Bioengineered · doi:10.1080/21655979.2022.2062533 · Cited by 97
“Diabetic retinopathy (DR) is one of the most common and major microangiopathic complications of diabetes mellitus, which can lead to retinal ischemia, retinal permeability changes and macular edema, eventually leading to visual impairment or even blindness [1,2].”
BackgroundStudy of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema
Dong, N., Xu, B., Chu, L., & Tang, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125329 · Cited by 99
Sandhu, H. S., Eladawi, N. H., Elmogy, M. M., Keynton, R. S., helmy, O., Schaal, S., & El-Baz, A. S. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-311489 · Cited by 92
Mahajan, N., Arora, P., & Sandhir, R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8458472 · Cited by 101
“Amongst 468 million people estimated with diabetes mellitus worldwide [8], approximately 90 million suffer with some form of diabetic retinopathy, [7].”
BackgroundArginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy
Sumarriva, K., Uppal, K., Ma, C., Herren, D. J., Wang, Y., Chocron, I. M., Warden, C., Mitchell, S. L., Burgess, L. G., Goodale, M. P., et al. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.19-27321 · Cited by 101
“Diabetic retinopathy (DR) is the leading cause of blindness in working-age adults, affecting approximately 93 million people worldwide.(1) Its prevalence will likely increase as the”
ExplAIn: Explanatory artificial intelligence for diabetic retinopathy diagnosis
Quellec, G., Hajj, H. A., Lamard, M., Conze, P.-H., Massin, P., & Cochener, B. (2021) · Medical Image Analysis · doi:10.1016/j.media.2021.102118 · Cited by 108
Zehden, J., Mortensen, X. M., Reddy, A. K., & Zhang, A. Y. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01491-y · Cited by 97
Oxidative Stress and Its Regulation in Diabetic Retinopathy
Haydinger, C. D., Oliver, G. F., Ashander, L. M., & Smith, J. R. (2023) · Antioxidants · doi:10.3390/antiox12081649 · Cited by 105
Computer-Aided Diagnosis in Ophthalmology: A Technical Review of Deep Learning Applications
Kazi, K. S. L. (2024) · Advances in healthcare information systems and administration book series · doi:10.4018/979-8-3693-3661-8.ch006 · Cited by 96
Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema
Kita, T., Clermont, A. C., Murugesan, N., Zhou, Q., Fujisawa, K., Ishibashi, T., Aiello, L. P., & Feener, E. P. (2015) · Diabetes · doi:10.2337/db15-0317 · Cited by 91
“Diabetic macular edema (DME) is a leading cause of vision loss among working-aged adults, with a global prevalence of ;16% for people with history of diabetes mellitus (DM) of $20 years (1).”
BackgroundPrevalence and causes of blindness and diabetic retinopathy in Southern Saudi Arabia
Hajar, S., Hazmi, A. A., Wasli, M. A., Mousa, A., & Rabiu, M. (2015) · Saudi Medical Journal · doi:10.15537/smj.2015.4.10371 · Cited by 91
Availability and variability in guidelines on diabetic retinopathy screening in Asian countries
Wang, L. Z., Cheung, C. Y., Tapp, R. J., Hamzah, H., Tan, G., Ting, D., Lamoureux, E., & Wong, T. Y. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-310002 · Cited by 91
Self-citationConversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema
Rahimy, E., Shahlaee, A., Ma, K., Ying, G., Maguire, J. I., Ho, A. C., Regillo, C. D., & Hsu, J. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.12.030 · Cited by 98
“Indeed, previous investigations have suggested that functional visual improvement may lag behind anatomic resolution of fluid in DME.32 It is interesting to note that the group of 22 eyes with at least 4 follow-up visits after switching to aflibercept experienced a visually significant improvement in logMAR VA compare…”
BackgroundInfluentialDiabetic Retinopathy in the Asia-Pacific
Chua, J., Lim, C. X. Y., Wong, T. Y., & Sabanayagam, C. (2019) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2017511 · Cited by 110
Self-citationDiaNet: A Deep Learning Based Architecture to Diagnose Diabetes Using Retinal Images Only
Islam, M. T., Al-Absi, H. R. H., Ruagh, E. A., & Alam, T. (2021) · IEEE Access · doi:10.1109/access.2021.3052477 · Cited by 95
Risk of Cardiovascular Diseases Is Increased Even with Mild Diabetic Retinopathy
Kawasaki, R., Tanaka, S., Tanaka, S., Abe, S., Sone, H., Yokote, K., Ishibashi, S., Katayama, S., Ohashi, Y., Akanuma, Y., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.08.029 · Cited by 91
Self-citationAhmed, R. A., Khalil, S. N., & Alqahtani, M. A. (2015) · Journal of Family and Community Medicine · doi:10.4103/2230-8229.172225 · Cited by 90
The relationship between diabetic retinopathy and psychosocial functioning: a systematic review
Khoo, K., Man, R. E. K., Rees, G., Gupta, P., Lamoureux, E. L., & Fenwick, E. K. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02165-1 · Cited by 89
“1 3 develop vision-threatening diabetic retinopathy (VTDR), which includes severe non-proliferative DR (NPDR), proliferative DR (PDR) and/or clinically significant macular edema (CSME) [2].”
BackgroundSelf-citationCost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China
Huang, X.-M., Yang, B.-F., Zheng, W.-L., Liu, Q., Xiao, F., Ouyang, P.-W., Li, M.-J., Li, X.-Y., Meng, J., Zhang, T.-T., et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07655-6 · Cited by 89
Corcóstegui, B., Durán, S., González-Albarrán, M. O., Hernández, C., Ruiz‐Moreno, J. M., Salvador, J., Udaondo, P., & Simó, R. (2017) · Journal of Ophthalmology · doi:10.1155/2017/8234186 · Cited by 90
“The percentages of DR may vary from 85% for insulin-dependent patients to 58% for noninsulin-dependent patients for more than 15 years after diagnosis [20].”
BackgroundTan, B., Chua, J., Lin, E., Cheng, J. W., Gan, A. T. L., Yao, X., Wong, D. W. K., Sabanayagam, C., Wong, D., Chan, C. M., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.19469 · Cited by 94
Self-citationSustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles
Tsujinaka, H., Fu, J., Shen, J., Yu, Y., Hafiz, Z., Kays, J. C., McKenzie, D. A., Cardona, D., Culp, D., Peterson, W. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14340-x · Cited by 89
Functional Carbon Quantum Dots for Ocular Imaging and Therapeutic Applications
Kumar, V. B., Sher, I., Rencus‐Lazar, S., Rotenstreich, Y., & Gazit, E. (2022) · Small · doi:10.1002/smll.202205754 · Cited by 91
Donovan, K., Alekseev, O., Qi, X., Cho, W., & Azizkhan‐Clifford, J. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14048 · Cited by 89
Sweet Stress: Coping With Vascular Dysfunction in Diabetic Retinopathy
Santiago, A. R., Boia, R., Aires, I. D., Ambrósio, A. F., & Fernandes, R. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00820 · Cited by 97
“Also, the increase in angiopoietin-2 produced by endothelial cells in the diabetic retina (Yao et al., 2007) induces astrocyte apoptosis and BRB impairment (Yun et al., 2016).”
BackgroundVolume-Rendered Optical Coherence Tomography of Diabetic Retinopathy Pilot Study
Spaide, R. F. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.09.010 · Cited by 88
Risk factors for diabetic retinopathy: a case–control study
Lima, V. C., Cavalieri, G. C., Lima, M. C., Nazário, N. O., & Lima, G. C. (2016) · International Journal of Retina and Vitreous · doi:10.1186/s40942-016-0047-6 · Cited by 105
“Although major risk factors—hyperglycemia and hypertension—are extensively studied and show a strong association with DR [16, 17], there are variations in consistency and pattern of these factors [2].”
BackgroundCHOROIDAL THICKNESS IN DIABETIC RETINOPATHY ASSESSED WITH SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY
Laíns, I., Talcott, K. E., Santos, A. R., Marques, J. H., Gil, P., Gil, J., Figueira, J., Husain, D., Kim, I. K., Miller, J. W., et al. (2017) · Retina · doi:10.1097/iae.0000000000001516 · Cited by 88
Aung, W. P., Htet, A. S., Bjertness, E., Stigum, H., Chongsuvivatwong, V., & Kjøllesdal, M. K. R. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020406 · Cited by 88
Curcumin Modulates DNA Methyltransferase Functions in a Cellular Model of Diabetic Retinopathy
Maugeri, A., Mazzone, M. G., Giuliano, F., Vinciguerra, M., Basile, G., Barchitta, M., & Agodi, A. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/5407482 · Cited by 94
“Since DR incidence is higher in type 1 diabetes patients [3], we firstly analysed microarray data of type 1 diabetes mouse models.”
BackgroundInfluentialArmstrong, G. W., & Lorch, A. (2019) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000298 · Cited by 96
CircRNA Is a Rising Star in Researches of Ocular Diseases
Zhang, C., Hu, J., & Yu, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00850 · Cited by 96
Panos, G. D., Lakshmanan, A., Dadoukis, P., Ripa, M., Motta, L., & Amoaku, W. M. K. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s427416 · Cited by 98
“DMO is characterised by the accumulation of fluid in the macula due to damaged blood vessels, while RVO-MO is caused by the occlusion of the retinal veins, leading to retinal hemorrhages and macular oedema.(4,5)”
BackgroundLee, C. S., Lee, A., Sim, D. A., Keane, P. A., Mehta, H., Zarranz‐Ventura, J., Fruttiger, M., Egan, C. A., & Tufail, A. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.09.041 · Cited by 94
“causes of blindness in working-age populations worldwide.(1) Initially described by Jaeger in 1855,(2) DR was mainly categorized into nonproliferative vs proliferative disease.”
Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology
Simó‐Servat, O., Simó, R., & Hernández, C. (2016) · Journal of Diabetes Research · doi:10.1155/2016/5263798 · Cited by 97
“having vision-threatening states such as diabetic macular edema (DME) or proliferative diabetic retinopathy (PDR) [2].”
BackgroundTen-Year Cumulative Incidence of Diabetic Retinopathy. The Beijing Eye Study 2001/2011
Xu, J., Xu, L., Wang, Y. X., You, Q. S., Jonas, J. B., & Wei, W. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111320 · Cited by 90
“As one of the leading causes of visual impairment and blindness in the middle-aged population, diabetic retinopathy (DR) has been an increasing threat to quality of life for millions of people worldwide [1–3].”
BackgroundSelf-citationWang, J. C., Laíns, I., Providência, J., Armstrong, G. W., Santos, A. R., Gil, P., Gil, J., Talcott, K. E., Marques, J. H., Figueira, J., et al. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.09.030 · Cited by 86
“Diabetic retinopathy (DR) is a major cause of visual loss worldwide and is estimated to affect up to 35% of patients with diabetes.(1) The pathogenesis of DR is primarily attributed to a dysregulation of the retinal vasculature, involving breakdown of the blood retinal barrier.”
BackgroundSelf-citationFilho, P. A. D. A. M., de Andrade, G. C., Maia, A., Maia, M., Neto, L. B., Neto, A. M., Brasil, O. F. M., Minelli, E., Dalloul, C., & Iglicki, M. (2018) · Ophthalmologica · doi:10.1159/000492132 · Cited by 86
A Global and Local Enhanced Residual U-Net for Accurate Retinal Vessel Segmentation
Lian, S., Li, L., Lian, G., Xiao, X., Luo, Z., & Li, S. (2019) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2019.2917188 · Cited by 91
Effects of Hypertension, Diabetes, and Smoking on Age and Sex Prediction from Retinal Fundus Images
Kim, Y. D., Noh, K. J., Byun, S. J., Lee, S., Kim, T., Sunwoo, L., Lee, K. J., Kang, S., Park, K. H., & Park, S. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-61519-9 · Cited by 96
Bairagi, R. D., Reon, R. R., Hasan, M. M., Sarker, S. K., Debnath, D., Rahman, M. T., Rahman, S., Islam, M. A., Siddique, M. A. T., Bokshi, B., et al. (2025) · Discover Nano · doi:10.1186/s11671-025-04234-6 · Cited by 92
“This disease develops in phases, from moderate non-proliferative abnormalities to more severe proliferative retinopathy, in which the retina’s surface becomes covered with new blood vessels [100].”
Are reactive oxygen species still the basis for diabetic complications?
Marco, E. D., Jha, J. C., Sharma, A., Wilkinson-Berka, J. L., Jandeleit-Dahm, K. A., & de Haan, J. B. (2015) · Clinical Science · doi:10.1042/cs20150093 · Cited by 86
The Blood-Retinal Barrier in the Management of Retinal Disease: EURETINA Award Lecture
Cunha-Vaz, J. G. (2017) · Ophthalmologica · doi:10.1159/000455809 · Cited by 91
GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Simó, R., & Hernández, C. (2017) · Diabetes · doi:10.2337/db16-1364 · Cited by 86
Pollack, S. J., Igo, R. P., Jensen, R. A., Christiansen, M. W., Li, X., Cheng, C., Ng, M. C. Y., Smith, A. V., Rossin, E. J., Segrè, A. V., et al. (2018) · Diabetes · doi:10.2337/db18-0567 · Cited by 92
“(6-8, 12, 13, 17, 18) Inclusion criteria for the discovery stage were (1) type 2 diabetes and (2) European or African American ethnicity.”
BackgroundMethodInfluentialSelf-citationRasti, R., Allingham, M. J., Mettu, P. S., Kavusi, S., Govind, K., Cousins, S. W., & Farsiu, S. (2020) · Biomedical Optics Express · doi:10.1364/boe.379150 · Cited by 85
“Diabetic macular edema (DME) is a major cause of central vision loss in patients with diabetic retinopathy if untreated [1].”
BackgroundThe endoplasmic reticulum: Homeostasis and crosstalk in retinal health and disease
Zhang, S. X., Wang, J. J., Starr, C. R., Lee, E.-J., Park, K. S., Zhylkibayev, A. A., Medina, A., Lin, J. H., & Gorbatyuk, M. S. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2023.101231 · Cited by 93
Self-citationThe Nigeria National Blindness and Visual Impairment Study Group, Kyari, F., Abubakar, T., Sivasubramaniam, S., Murthy, G. V. S., Pető, T., & Gilbert, C. E. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-1299 · Cited by 85
Performance of an iPad Application to Detect Moderate and Advanced Visual Field Loss in Nepal
Johnson, C. A., Thapa, S. S., Kong, Y. X. G., & Robin, A. L. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.08.007 · Cited by 85
Ting, D. S. W., Cheung, C. Y., Nguyen, Q., Sabanayagam, C., Lim, G., Lim, Z. W., Tan, G. S. W., Soh, Y. Q., Schmetterer, L., Wang, Y. X., et al. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0097-x · Cited by 82
Self-citation
Metadata
- Authors
- Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., Porta, M., Rema, M., Roy, M. S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J. M., Varma, R., Wang, J. J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T. Y., & for the Meta-Analysis for Eye Disease (META-EYE) Study Group
- Affiliations
- The University of Melbourne (AU)
- Allergan (United States) (US)
- Aarhus University Hospital (DK)
- Taipei Veterans General Hospital (TW)
- Amsterdam Public Health (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Odense University Hospital (DK)
- Shavano Park, Texas
- Colorado School of Public Health (US)
- Erasmus MC (NL)
- Yamagata University (JP)
- University of Wisconsin–Madison (US)
- L V Prasad Eye Institute (IN)
- Samut Sakhon Hospital (TH)
- University of Warwick (GB)
- University of Pittsburgh (US)
- University of Turin (IT)
- Madras Diabetes Research Foundation (IN)
- Rutgers New Jersey Medical School (US)
- Sankara Nethralaya (IN)
- Baker Heart and Diabetes Institute (AU)
- Johns Hopkins University (US)
- University of Southern California (US)
- The University of Sydney (AU)
- Beijing Tongren Hospital (CN)
- Johns Hopkins Hospital (US)
- Kyushu University (JP)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Wong, Tien Y.
- ORCID
- Rogers, Sophie L.
- Kawasaki, Ryo
- Lamoureux, Ecosse L.
- Bek, Toke
- Chen, Shih-Jen
- Fletcher, Astrid
- Grauslund, Jakob
- Hamman, Richard F.
- Ikram, M. Kamran
- Klein, Barbara E.K.
- Klein, Ronald
- Krishnaiah, Sannapaneni
- Mayurasakorn, Korapat
- Orchard, Trevor J.
- Porta, Massimo
- Sharma, Tarun
- Shaw, Jonathan
- Taylor, Hugh
- Tielsch, James M.
- Varma, Rohit
- Wang, Jie Jin
- West, Sheila
- Xu, Liang
- Zhang, Xinzhi
- Mitchell, Paul
- Wong, Tien Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322721
- OpenAlex
- W2138480916
- Cited by
- 4,985
- References
- 38
- Citations by year
- 2026: 374 · 2025: 447 · 2024: 477 · 2023: 429 · 2022: 499 · 2021: 544 · 2020: 520 · 2019: 365 · 2018: 331 · 2017: 305 · 2016: 238 · 2015: 198 · 2014: 139 · 2013: 80 · 2012: 30
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Hyderabad Eye Research Foundation
- Oogfonds
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- National Institutes of Health
- Allergan
- Medical Research Council
- National Eye Institute (EY0-6594, R01 EY 09860, R01EY009860, U10EY006594, R01EY016379)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, global prevalence, risk factors, diabetes duration, glycemic control, HbA1c, blood pressure, type 1 diabetes, type 2 diabetes, fundus images, public health burden
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.